Stomach cancer drug combo trial halted early
Disease control
Terminated
This study tested a new drug called DKN-01 combined with tislelizumab and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that could not be removed by surgery. The trial aimed to see if the combination was safe and slowed cancer growth. It enroll…
Phase: PHASE2 • Sponsor: Leap Therapeutics, Inc. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC